Intellectual Property India Publishes Patent Application for 'Peptide Inhibitors Of Interleukin-23 Receptor' Filed by Janssen Pharmaceutica NV; and Protagonist Therapeutics, Inc.

MUMBAI, India, Aug. 22 -- Intellectual Property India has published a patent application (202517074166 A) filed by Janssen Pharmaceutica NV; and Protagonist Therapeutics, Inc., Beerse, Belgium, on Aug. 4, for 'peptide inhibitors of interleukin-23 receptor.'

Inventor(s) include Barros, Stephanie A.; Neelamkavil, Santhosh Francis; Sun, Chengzao; Guo, Boying; Hendrick, Charles; Marcoux, David; Somani, Sandeep; Thieu, Tho; Zhang, Jing; Branca, Danila; Costante, Roberto; Bhandari, Ashok; Bourne, Gregory Thomas; and Frederick, Brian Troy.

The application for the patent was published on Aug. 22, under issue no. 34/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure relates to peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders."

The patent application was internationally filed on Jan. 15, 2024, under International application No.PCT/US2024/011537.

Disclaimer: Curated by HT Syndication.